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Abstract 
Impact on the timing of first postpartum VTE for women with specific risk factors is of 
crucial importance when planning the duration of thromboprophylaxis regimen. We observed 
this using a large linked primary and secondary care database containing 222,334 pregnancies 
resulting in live and stillbirth births between 1997 and 2010. We assessed the impact of risk 
factor on the timing on postpartum VTE in term of Absolute rate (AR) and incidence rate 
ratios (IRR) using Poisson regression model. Of the factors associated with any increased 
postpartum VTE risk, women with preeclampsia/eclampsia and puerperal infection had the 
highest risk of VTE in during the first three weeks postpartum (ARs≥2263/100,000 person-
years IRR≥2.5) and at 4-6 weeks postpartum (AR≥1360;IRR≥3.5). Women with 
BMI>30Kg/m2 or those having caesarean delivery also had elevated rates up to 6 weeks 
(ARs≥1,425 at 1-3 weeks; and AR≥722 at 4-6 weeks). Women with postpartum haemorrhage 
or preterm birth, had significantly increased VTE rates only in the first 3 weeks (ARs≥1736, 
IRR≥2) after which the relative risk became statistically non-significant. Our findings 
suggests that the duration of the increased VTE risk after childbirth varies based on the type 
of risk factors and can extend up to the first 3-6 weeks postpartum. 
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Key points  
 
 Women with preeclampsia, BMI>30Kg/m2, infection or those having caesarean 
delivery, the VTE risk remained elevated for 6 weeks postpartum. 
 
 For women with postpartum haemorrhage or pre-term birth, the relative rate of VTE 
was only increased for the first 3 weeks postpartum.  
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Introduction 
Venous thromboembolism (VTE) is a preventable serious maternal complication1, 2 most 
likely to occur during the postpartum period.3-5 Whilst a number of studies6-9 have identified 
risk factors for VTE during the postpartum period, there is a lack of evidence quantifying 
how the impact of risk factors on the incidence of VTE may differ from early to later 
postpartum periods. The United Kingdom Royal College of Obstetricians and Gynaecologist 
(RCOG)10 and the American College of Chest Physician (ACCP)11 guidelines currently 
recommend seven days or in-hospital pharmacological postpartum thromboprophylaxis 
respectively for women with two or more minor risk factors (e.g. smoking, postpartum 
haemorrhage, pre-eclampsia, caesarean section, obesity) if they have had no previous VTE. 
These guidelines however are based on expert clinical consensus rather than on robust 
evidence. Such evidence for the impact on the timing of postpartum VTE for women with 
specific risk factors is of crucial importance when planning the duration of 
thromboprophylaxis regimens.12 Although a large study by Kamel et.al13 recently looked at 
the risk of VTE during specific postpartum periods; however they were unable stratify those 
risk by different risk factors.    
 
Previously our group comprehensively reported the risk factors of VTE during the 
postpartum period in terms of absolute risks.14 However, due to the uncertainty of timing of 
VTE recorded in primary care data, we were then unable to assess the risk of VTE during 
specific postpartum periods by risk factors. Similarly, previous studies have also failed to 
report those estimates. Recently linked primary and secondary care data that are 
representative of the English population provide better information on the timing of VTE 
than solely using primary care data particularly during the specific postpartum periods.15 
Therefore our aim was to assess the risk of VTE during specific postpartum periods 
according to women’s risk profiles using these prospectively collected primary and secondary 
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care data.  We employed multiple modelling frameworks based on a conceptual hierarchical 
framework first to such identify risk factors and assess the effects of mutual confounding and 
mediation by certain risk factors.  
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Methods 
Study population  
We used the Clinical Practice Research Datalink (CPRD) 16 which is a large longitudinal UK 
database that contains computerised primary care (i.e. general practice) records of 
anonymised patients. Approximately 98% of the England and Wales population are registered 
with general practitioners (GPs), who are responsible for almost the entirety of a patient’s 
medical care, including coordination of their health care from hospital or other secondary 
care facilities. The CPRD includes practices who have been trained to record information 
using the Vision software and who have consented to be included in the database. All patients 
within a consented practice are automatically included. Around 53% of the CPRD practices 
are linked to Hospital Episode Statistics (HES)17 data which contains information on all 
hospitalisations in England including all discharge diagnoses and procedures. The 
anonymised patient identifiers from CPRD and HES were linked by a trusted third party 
using National Health Service (NHS) number, date of birth, postcode and gender.18 First, 
patients were matched exactly according to NHS number (over 90% of patients are linked in 
this way), with the remaining patients linked probabilistically on the basis of postcode, date 
of birth and gender.  As HES only covers English hospitals, practices from Northern Ireland, 
Wales and Scotland were excluded. Previously data from the linked portion of the CPRD 
have been shown to be representative in terms of age and sex distribution to data from the 
UK population published by the Office for National Statistics (ONS). Diagnoses of VTE in 
primary care19 and birth information in HES maternity data20 have been validated to external 
sources with accuracy with positive predictive values of 84% and 90% respectively. Women 
aged 15-44 years with HES-recorded pregnancies ending in live birth or stillbirth between 
1997 and 2010 and with no VTE before or during pregnancy (as determined from their 
longitudinal clinical record) were identified within our study population. We therefore had 
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prospectively recorded health and socio-demographic information for women before and 
during pregnancy and after delivery. 
 
Defining postpartum venous thromboembolism 
We defined first VTE using Read and ICD-10 diagnosis codes for pulmonary embolism or 
deep vein thrombosis in CPRD and HES respectively (taking the earliest date as the date of 
diagnosis if the event was recorded in both databases).  For VTE events first recorded in 
HES, the date of VTE was taken as the date of hospital admission. The diagnosis was 
accepted if supported by one of the following: a prescription of heparin or warfarin within 90 
days of diagnosis, evidence of anticoagulant therapy or attendance at an anticoagulant clinic 
within 90 days of diagnosis, or death within 30 days of diagnosis. Rates of VTE ascertained 
using this definition have been demonstrated to be highly comparable to incidence rates of 
VTE in and around pregnancy across other high-income countries and estimation of the date 
of clinical diagnosis of VTE during specific postpartum periods has been found to be 
accurate.15 As 90% of deliveries occurred on the day women were admitted to hospital for 
delivery or on the day after, the postpartum period was defined from one day before up to 12 
weeks post-delivery. This was to ensure complete capture of all pregnancy-related VTE 
diagnosed during the postpartum period.  
 
Defining potential risk factors 
Demographics, lifestyle characteristics and pre-existing co-morbidities 
For all pregnancies we extracted information on women’s demographic and lifestyle 
characteristics as well as important co-morbidities from both primary and secondary care 
data. Information on body mass index (BMI) (Kg/m2), cigarette smoking (current, ex-smoker 
or non-smoker), ethnicity (white or non-white) and age at delivery were obtained from CPRD 
data, whilst cardiac disease, varicose veins, inflammatory bowel disease (IBD), pre-existing 
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diabetes and hypertension were ascertained using both CPRD and HES using methods similar 
to previously described using primary care data.14 Similarly we defined women as having 
pre-existing renal disease if they had a diagnosis of acute or chronic kidney disease, 
glomerular or renal tubule-interstitial disease before conception in HES or CPRD. 
 
Pregnancy characteristics and complications 
Pre-eclampsia/eclampsia, hyperemesis, multiple birth, gestational diabetes or hypertension as 
previously defined14 were extracted using both CPRD and HES. We also investigated two 
common acute systemic infections during pregnancy (urinary and respiratory tract 
(pneumonia, acute bronchitis, chest infection and influenza)) as these have been associated 
with VTE in non-pregnant populations.21, 22 
 
Delivery characteristics and complications 
From HES we extracted risk factors occurring around delivery: length of gestation, mode of 
delivery (spontaneous, assisted (forceps, breech or vacuum), emergency or elective 
caesarean), stillbirth, and postpartum haemorrhage (including intra-partum haemorrhage). We 
also investigated acute systemic infections during the postpartum period, termed puerperal 
infection. 
 
Statistical analysis 
We calculated incidence rates of VTE per 100,000 person-years and 95% confidence 
intervals by dividing the number of VTEs by the postpartum follow-up time, stratified by 
each demographic and lifestyle characteristic, pre-existing co-morbidity, pregnancy and 
delivery characteristic and complication. Using Poisson regression we calculated unadjusted 
incidence rate ratios (IRR) for the associations between each risk factor and VTE. We fitted a 
clustering term to take into account multiple pregnancies experienced by an individual 
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woman over the study period. For associations where the likelihood ratio (LRT) test p-value 
was <0.1 we included these risk factors in multivariate models that were constructed using a 
pre-developed conceptual hierarchical framework (Figure 1) as a tool to assess the complex 
causal pathways between variables.23 For instance, some of the impact of delivery 
complications (e.g. mode of delivery, postpartum haemorrhage) on postpartum VTE may be 
confounded by pregnancy characteristics (e.g. pre-eclampsia), pre-existing medical co-
morbidities (e.g. cardiac disease) or demographic factors (e.g. maternal age), however each of 
these factors may also have direct effects on postpartum VTE that are not mediated through 
delivery complications. 
 
In our hierarchical framework we grouped factors that were considered to have more 
proximate associations with postpartum VTE (e.g. caesarean section) separately from more 
distant factors (e.g. pre-pregnancy BMI) that may have direct effects on VTE but may also 
have indirect effects mediated through proximate risk factors (e.g. pre-pregnancy BMI is 
related to one’s likelihood of developing pre-eclampsia, the latter being a more proximate 
risk factor for VTE).24 Based on this we created three modelling frameworks (MF) to present 
rate ratio estimates adjusted for different groups of risk factors.  In modelling framework 1 
we created separate models for each pre-existing co-morbidity, pregnancy and delivery 
characteristic/complication to estimate their overall effects on postpartum VTE, adjusting 
only for demographic and lifestyle characteristics (maternal age, BMI, cigarette smoker). In 
MF 2, models from MF 1 were additionally adjusted for any pre-existing medical co-
morbidities (e.g. cardiac disease). In MF 3, models were adjusted for demographic and life 
style related factors, pre-existing medical co-morbidities and pregnancy related 
characteristics and complications, to estimate each of their effects unmediated by their more 
proximate risk factors, and also the fully adjusted effects of each delivery 
characteristic/complication. At that point we re-added statistically non-significant variables 
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previously excluded to assess if they became significant. Because the direction of causal 
pathways between caesarean delivery and other delivery complications (e.g. stillbirth) can 
vary, we carried out a subgroup analysis restricting to women who only underwent 
spontaneous vaginal or assisted delivery.  
 
For pregnancy and delivery complications showing increased postpartum VTE risks with 
more than 10 associated VTE events (to ensure reasonable precision), we assessed whether 
the absolute and relative risks (AR and RR) of VTE differed during the early postpartum 
(weeks 1-3 and weeks 4-6 post-delivery) and late postpartum (weeks 7-12 post-delivery). For 
the purpose of this analysis we also evaluated the risk of VTE within the one year after the 12 
weeks postpartum period (one year from 13th weeks). Although the rate of VTE expressed as 
per 100,000 person-years during postpartum periods helps in standardization and comparison 
of the estimates, we also calculated the rate of VTE per 100,000 pregnancies which are of 
clinical value. We used those estimates to calculate the Number Needed to Treat (NNT) to 
prevent one VTE assuming that thromboprophylaxis reduces the VTE risk by 50% based on 
the randomised trials of general medical patients.25 We also calculated the NNT based on the 
88% risk reduction observed among non-randomised pregnant women.26  
 
For our sensitivity analysis, we re-ran all models, excluding a small proportion (7%) of VTE 
events first recorded in HES because they occurred during the same hospital admission as the 
delivery or another risk factor event (e.g. postpartum haemorrhage) and therefore precise 
temporality could not be established (i.e. we could not determine whether VTE was the cause 
or consequence of a caesarean section or postpartum haemorrhage, particularly for those 
occurring on the same day). 
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Results  
 
Among 168,077 women there were 222,334 pregnancies ending in live birth or stillbirth. 
There were a total of 178 VTE events which occurred during the postpartum period. Table 1 
shows absolute rates of postpartum VTE and associations with each of the 21 risk factors 
assessed, 14 of which were significantly associated with postpartum VTE in bivariate models 
(LRT p<0.01).  
 
Multivariate analyses of postpartum VTE risks 
When we assessed the direct and mediated effects of each factor using different modelling 
frameworks (Figure 1 and Table 2), we found that high BMI was associated with increased 
postpartum VTE risk across all three models indicating that little of the obesity-associated 
risk was mediated through other factors, pre-existing, or pregnancy related. Similarly there 
were almost 4-fold and 3-fold increased risks for women previously diagnosed with varicose 
veins and cardiac disease respectively, which did not appear to be strongly mediated by other 
risk factors. For delivery characteristics and complications we found a 7-fold (95%CI 3.33-
15.4) increased risk of VTE for those with stillbirth even after adjusting for important 
background factors. Elective caesarean and emergency caesarean, puerperal infection and 
pre-term birth were associated with at least 2-fold increased risks compared to spontaneous 
vaginal deliveries, those with no puerperal infection, with normal gestational length 
respectively. These factors were still important even after adjusting for women’s pre-existing 
co-morbidities and factors occurring prior delivery. The increased risk of VTE observed with 
BMI ≥30 Kg/m2 and caesarean section remained consistent when we restricted our analysis to 
women without any other risk factor (Supplementary table 1). 
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Even among women with spontaneous vaginal deliveries, stillbirth, postpartum haemorrhage, 
puerperal infection, pre-term birth, pre-eclampsia/eclampsia, varicose veins and 
BMI≥30Kg/m2 were still associated with increased risks (Table 2). No associations changed 
when we excluded the 7% of VTE events occurring during the same hospital admission as the 
delivery or risk factor event where we could not establish their relative order. 
 
Variation in VTE incidence and incidence rate ratios during postpartum periods 
When we ascertained absolute risks of VTE within specific postpartum intervals (Table 3), 
we found that women with preeclampsia/eclampsia and puerperal infection had the highest 
risk of VTE in during the first three weeks postpartum (AR=2263 and AR=4813 per 100,000 
person-years respective). The risk also remained elevated in the 4-6 weeks postpartum for 
those risk factors, although to a lesser extent (AR>890 per 100,000 person-years). Women 
with BMI>30Kg/m2 or those who had caesarean delivery, also had elevated rate of VTE up to 
6 weeks postpartum (ARs>1,400/100,000 person-years in weeks 1-3 and >700 in weeks 4-6). 
However for women with postpartum haemorrhage or pre-term birth, the relative rate of VTE 
was only increased for the first 3 weeks postpartum (ARs=1-2/100 person-years). Within a 
year after the 12 weeks postpartum (Figure 2) the absolute rate of VTE associated with those 
risk factors became similar to that of non-pregnant women of childbearing age (30/100,000 
person-year). Our absolute rates of VTE for the above stated risk factors were broadly similar 
when restricted to the first week compared to those over weeks 1-3 postpartum 
(Supplemental table 2).  
 
Number needed to treat during weeks of postpartum 
Table 4 contains the risk of VTE per 100,000 pregnancies and NNT for each specific risk 
factor. Based on a 50% risk reduction we observed that during the first three weeks of 
postpartum, the lowest NNT was 1,173 for women with puerperal infection, followed by 
14 
 
women with pre-eclampsia/eclampsia (NNT=1,289). The NNT values were all around 1,600 
for women preterm births, postpartum haemorrhage or BMI>30Kg/m2. At 4-6 weeks 
postpartum, the lowest NNT was for women with pre-eclampsia/eclampsia (NNT=2,557) 
followed by BMI>30Kg/m2 (NNT=4,734) and caesarean section (NNT=4,816). 
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Discussion 
Main findings 
This study provides precise absolute and relative risks of postpartum VTE for maternal risk 
factors occurring before, during and after childbirth and quantifies which have the greatest 
impact on VTE during specific postpartum intervals. We found that women with stillbirths, 
per-term birth, postpartum haemorrhage, puerperal infection, caesarean delivery and high 
BMI (>30Kg/m2) were at a high risk of postpartum VTE. The augmented risks associated 
with these factors were not explained by other pregnancy characteristics and complications, 
pre-existing co-morbidities, demographics or lifestyle factors considered in this study. We 
found that for women with preeclampsia/eclampsia, BMI>30Kg/m2, puerperal infection or 
those having caesarean delivery, the rate of VTE remained elevated for 6 weeks postpartum. 
However for women with postpartum haemorrhage or pre-term birth, the relative rate of VTE 
was only increased for the first 3 weeks postpartum with NNTs of 933 and 956 respectively.   
 
Strengths and weaknesses 
Our study used information on more than 222,000 pregnancies with postpartum follow-up 
using linked primary and secondary care data which covers 3% of the UK population and has 
similar age and sex distribution to the national population. Our study findings are therefore 
reasonably generalisable to pregnant women in England with no prior diagnosis of VTE and 
to women in other high-income countries with similar health care systems. By using linked 
primary and secondary care data we had comprehensive medical information on women’s 
baseline health risks recorded before pregnancy as well as their pregnancy and delivery 
health records, all of which were prospectively recorded. This enabled us not only to assess 
the impact of risk factors on postpartum VTE while adequately controlling for confounding 
factors but also to assess the impact of risk factors on the incidence of VTE during specific 
postpartum periods. 
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Another strength of this study was our use of a conceptual hierarchical framework to adjust 
our estimates for potential confounding factors. Most previous studies have used stepwise 
regression models for their risk factor analysis. This is solely reliant on statistical association 
rather than any conceptual basis for the interrelationship between factors where all 
explanatory variables are treated at the same hierarchical level, an assumption which may not 
be appropriate in all cases particularly for closely related factors around pregnancy and 
delivery. In contrast our categorisation of risk factors and adjustments in hierarchical order 
enabled us to better evaluate the extent to which the effect of a particular risk factor had a 
direct effect or was mediated by other risk factors. (e.g. whether the effect of stillbirth is 
mediated by more distant risk factors such as age and/or BMI). 
 
A limitation of this analysis is our inability to establish temporality between VTE and risk 
factors that were recorded during the same hospital admission as the VTE event (e.g. 
postpartum haemorrhage). However this only affected 7% of our cases and our sensitivity 
analysis demonstrated that removing those women from our analysis did not affect our 
estimates.   We also acknowledge that we were not able to consider certain risk factors such 
as family history of VTE and thrombophilia. However we believe that the following 
arguments should be considered. Firstly, whilst family history may be important, it has rarely 
been looked at in previous population-based studies, possibly for the reason that accurate 
recall of a family history is problematic. Secondly thrombophilia screening is not routinely 
recommended for pregnant women therefore pragmatically it cannot be used as a predictor 
for VTE outcome.  
 
The hospital and general practice data used in our study is directly from routinely 
implemented clinical practice provided by the UK National Health Service which is free at 
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the point of access, and whilst VTE has been validated with reasonably accuracy,15, 19 there is 
a lack of validation studies on medical codes for pregnancy-related risk factors such as pre-
eclampsia, postpartum haemorrhage. However a systematic review of overall discharge 
diagnosis coding in HES has demonstrated high accuracy (91%). Whilst there are a very 
limited number of studies estimating the population-based prevalence of pregnancy-related 
illnesses, the prevalence of hypertension, pre-eclampsia, diabetes, caesarean section, 
stillbirths, postpartum haemorrhage and preterm births in our population were very similar to 
the available evidence from national or other similarly developed countries.27-33 
 
We would also like to highlight that, because prescriptions are available from general practice 
but not from hospital data,15 our estimates do not take into account that certain women may 
have been receiving thromboprophylaxis during the risk periods assessed, which may have 
led to an underestimation of risk.  However, we believe that since the first RCOG guidelines 
for postnatal thromboprophylaxis were only published in 2004 (updated 2009), the use of 
thromboprophylaxis with LMWH was unusual before 2004 except for those women with 
previous VTE. There is also evidence suggesting the underuse of prophylaxis among post 
caesarean section women.34 Additionally, 67% of all pregnant women diagnosed with 
antepartum pulmonary embolism (between 2005 and 2006) in the UK did not receive 
pharmacological thromboprophylaxis according to national guidelines even though they 
qualified for thromboprophylaxis35 so we do not believe this would have resulted in 
substantial underestimation.  
 
Finally we acknowledge that some of the numbers in our postpartum analysis are small which 
could lead to type 2 error. However a large study conducted by Kamel et al13(which utilised 
information on 1.6 million pregnancies but did not assess risk factors) showed an overall 
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elevated risk of thrombosis which persisted until at least 12 weeks after delivery. This might 
be due to certain risk factors which we have highlighted in our study. 
 
Comparison with other literature 
Our relative increased risks observed for women with BMI≥30Kg/m2, cardiac disease, 
varicose veins, pre-eclampsia/eclampsia and puerperal infection are in concordance with 
most previous studies.6, 7, 9, 36-38 Additionally our study findings support increased risks of 
more than 2-fold and 6-fold in women experiencing pre-term delivery and stillbirth 
respectively, both of which have been previously reported.9, 14, 37 We also found a 2-fold 
relative increase in the risk of VTE for both elective and emergency caesarean delivery 
compared to spontaneous vaginal delivery. Our finding of an increased risk of VTE 
associated with elective caesarean section contradicts that of Jacobsen et al36 who only found 
an increased VTE risk associated with emergency caesarean section.  Jacobsen et al36, 
however, obtained VTE cases using a patient registry for the whole population of Norway 
and controls from a single hospital where they had many more elective caesarean sections 
(9.2%) compared to the general population (4.8%), which may have biased their estimates 
towards null. Similarly to previous studies, we were not able to look at the reasons for 
caesarean section in more detail, for example the urgency grade of the caesarean section39 as 
clinical classification of emergency and elective caesarean section in practice remains crude. 
 
We found only one published study evaluating the impact of multiple risk factors on the 
absolute and relative rates of VTE in different specific postpartum periods. Morris et al37 in a 
population-based study from Australia showed that a high absolute rate of pulmonary 
embolism (PE) persists for up to 4 weeks after caesarean delivery. This may have been 
underestimated as only secondary care data were used to identify PE cases and hospital 
admission date was considered as the date of diagnosis. The higher relative risk of VTE that 
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we found associated with obesity and caesarean delivery in weeks 4-6 following delivery 
than in the first three weeks may be explained by the fact that those women would have 
received some form of thromboprophylaxis during the initial postpartum week, as suggested 
by the current thromboprophylaxis guidelines, which we were not able to quantify. However 
there was no overall statistical difference in the rate of VTE among those with caesarean 
section or BMI≥30Kg/m2 when we assessed this before and after 2004. 
 
We were also not able to calculate the absolute rate of VTE during the specific postpartum 
periods among those with stillbirths due to insufficient power. However 75% (n=6) of VTE 
cases occurred during the first 3 weeks postpartum which highlights the importance of VTE 
risk assessment during that period. Finally our calculated NNTs during those periods should 
be interpreted with caution as they are based on non-trial data regarding the reduction in risk 
after low molecular weight heparin in non-pregnant populations. 
 
Clinical implication  
Our results have important implications for deciding how and when thromboprophylaxis is 
delivered in the obstetric health care setting and will help targeting of thromboprophylaxis in 
the following ways; Firstly, our results suggest that the increased risk of VTE extends beyond 
the currently suggested 7 days for women with certain risk factors. Secondly we found that 
for women with preeclampsia/eclampsia, BMI>30Kg/m2, puerperal infection or those having 
caesarean delivery, the rate of VTE remained elevated for 6 weeks postpartum. However for 
women with postpartum haemorrhage or pre-term birth, the relative rate of VTE was only 
increased for the first 3 weeks postpartum with a NNT of 1739. This suggests that the time 
period of increased risk of VTE during the postpartum is dependent on the type of risk factors 
which should be considered when planning thromboprophylaxis. Finally, women whose 
pregnancies are complicated by stillbirth, high BMI, pre-term birth, caesarean section, 
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puerperal infection or postpartum haemorrhage should be considered at high risk (AR=0.6-
2.5 per 100 person-years) of VTE postnatally. The augmented risks associated with these 
factors are not explained by other pregnancy characteristics and complications, pre-existing 
co-morbidities, demographics or lifestyle factors. Therefore pregnancies complicated by any 
one of those factors may require careful consideration in terms of VTE risk assessment 
during the immediate postpartum. 
 
Recommendations regarding postpartum thromboprophylaxis with low molecular weight 
heparin for women with the above highlighted risk factors will of course be highly dependent 
on the risk reduction from prophylaxis and any adverse events from its use.  Nevertheless our 
study provides the most robust, comprehensive and clinically relevant information on risk 
factors for postpartum VTE that can be of direct use in formulating such guidelines.   
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Table 1: Incidence rates of postpartum VTE per 100,000 person-years and IRRs for  
potential delivery, pregnancy and pre-existing risk factors (222,334 pregnancies) 
Variable  Pregnancies  
N (%)  
Total=222,334 
Postpartum 
VTE N 
Total=178 
Rate(95%CI)* 
 
IRR (95%CI) 
Unadjusted 
Demographic and lifestyle characteristics  
Maternal age at delivery     
15 – 19 years 12,927 (5.8) 5 170 (70-408) 0.43 (0.17-1.08) 
20 – 24 years  36,960 (16.6) 28 330 (228-478) 0.84 (0.53-1.33) 
25 -  29 years 58,207 (26.1) 53 390 (298-551) 1.00 
30 – 34 years 68,753 (30.9) 37 228 (165-315) 0.58 (0.38-8.90) 
35 – 39 years 37,968 (17.0) 44 491 (366-661) 1.25 (0.84-1.87) 
40 – 44 years 7,519 (3.3) 11 325 (346-1130) 1.60 (0.83-3.06) 
     
Body mass index (Kg/m2)     
Normal(18.5-24.9) 98,730 (44.4) 60 259 (201-334) 1.00 
Underweight(<18.5) 7,339 (3.30) 3 179 (56-545) 0.67 (0.21-2.16) 
Overweight(25-29.9) 39,652 (17.8) 33 353 (252-499) 1.36 (0.89-2.09) 
Obese(30-40) 21,410 (9.6) 28 558 (385-808) 2.14 (1.37-3.36) 
Class 3 obese (>40) 2,731 (1.2) 12 1881 (1068-3312) 7.24 (3.89-13.4) 
     
Ethnicity      
White  159,159 (71.5) 129 347 (292-412) 1.00 
Non white  21,178 (9.5) 21 430 (280-658) 1.23 (0.78-1.96) 
Missing  41,997 (18.8) 28 284 (196-411) 0.81 (0.54-1.23) 
     
Cigarette smoker 51,731 (23.2) 51 424 (322-558) 1.24 (0.88-1.76) 
Ex-smoker 55,743 (25) 36 275 (198-382) 0.81 (0.55-1.19) 
Pre-existing co-morbidities 
Varicose veins 5,895 (2.65) 16 1154 (707-1884) 3.59 (2.15-6.01) 
Cardiac disease 2,264 (1.0) 5 945 (393-2271) 2.80 (1.15-6.83)) 
Inflammatory bowel disease 1,105 (0.5) 4 1545 (580-4117) 4.58 (1.69-12.3) 
Pre-existing hypertension 13,814 (6.5) 17 524 (326-844) 1.68 (1.01-2.78) 
Pre-existing diabetes  2,501 (1.1) 4 685 (257-1826) 2.03 (0.75-5.46) 
Pre-existing renal disease 1,493 (0.7) 2 575 (143-2300) 1.68 (0.41-6.78) 
Pregnancy characteristics and complications  
Antepartum haemorrhage 10,329 (4.6) 10 416 (224-774) 1.22 (0.64-2.31) 
Acute systemic infection 26,572 (11.9) 20 323 (208-550) 0.93 (0.58-1.48) 
Pre-eclampsia/eclampsia 5,237 (2.3) 14 1148 (679-1938) 3.54 (2.05-6.11) 
Multiple birth  3,282 (1.4) 3 390 (125-1211) 1.14 (0.36-3.57) 
Gestational hypertension 11,796 (5.6) 18 655 (413-1041) 2.10 (1.28-3.43) 
Gestational diabetes 3,518 (1.6) 4 486 (182-1294) 1.44 (0.53-3.88) 
Hyperemesis 7,838 (3.53) 9 494 (257-950) 1.46 (0.74-2.86) 
Delivery characteristics and complications  
Length of gestation      
Normal gestation  184,744 (83.0) 15 313 (264-370) 1.00 
Pre-term gestation  17,112 (7.7) 29 727 (505-1047) 2.31 (1.55-3.46) 
Prolonged gestation 20,478 (9.2) 14 293 (173-494) 0.93 (0.53-1.62) 
     
Mode of delivery      
Spontaneous  141,1207 (63.5) 76 230 (184-288) 1.00 
Assisted  26,943 (12.1) 19 304 (194-476) 1.31 (0.79-2.18) 
Elective caesarean  22,341 (10.0) 33 630 (448-886) 2.73 (1.81-4.11) 
Emergency caesarean  31,843 (14.3) 50 674 (511-890) 2.92 (2.04-4.18) 
     
Stillbirth 1,356 (0.61) 8 2595 (1297-5189) 7.86 (3.87-15.9) 
Postpartum haemorrhage 20,762 (9.34) 30 629 (440-900) 2.00 (1.35-2.96) 
Puerperal infection 7,740 (3.4) 18 1291 (813-2049) 4.07 (2.50-6.63) 
*Rate calculated per 100,000 person-years. IRR: Incidence rate ratio CI: confidence interval  
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Table 2: Multivariate analysis for VTE risk factors during the postpartum period  
 Incidence rate ratios (95%CI) 
Variable   Modelling 
framework 1  
 Modelling 
framework 2 
 Modelling 
framework 3 
 Modelling framework 3 
restricted to 
Spontaneous  
vaginal/Assisted 
deliveries 
 
Demographic and lifestyle characteristics 
Maternal age at delivery     
Age (for every years increase)◊ 1.03 (1.00-1.06) 1.02 (0.99-1.05) 1.02 (0.99-1.05) 1.02 (0.98-1.07) 
     
Body mass index (Kg/m2)     
Normal(18.5-24.9) 1.00 1.00 1.00 1.00 
Underweight(<18.5) 0.70 (0.21-2.27) 0.69 (0.21-2.23) 0.74 (0.23-2.39) 0.84 (0.19-3.56) 
Overweight(25-29.9) 1.35 (0.88-2.07) 1.36 (0.89-2.09) 1.21 (0.77-1.90) 0.67 (0.30-1.46) 
Obese(30-40) 2.13 (1.36-3.34) 2.15 (1.37-3.37) 1.91 (1.18-3.11) 2.57 (1.37-4.82) 
Class 3 Obese(≥40) 7.23 (3.89-13.4) 7.45 (4.00-13.8) 6.36 (3.19-12.6) 11.5 (4.96-26.6) 
     
Cigarette smoker 1.43 (1.03-1.99) 1.44 (1.04-2.00) 1.38 (0.97-1.96) 1.16 (0.71-1.89) 
     
Pre-existing co-morbidities 
Varicose veins 3.50 (2.09-5.87) 3.50 (2.09-5.78) 3.97 (2.36-6.68) 4.88 (2.61-9.11) 
Cardiac disease 2.67 (1.09-6.53) 2.59 (1.05-6.33) 2.78 (1.02-7.53) 2.69 (0.66-10.9) 
Inflammatory bowel disease 4.59 (1.69-12.4) 4.61 (1.70-12.4) 2.62 (0.64-10.6) ** 
Pre-existing hypertension 1.46 (0.88-2.43) - - - 
     
Pregnancy characteristics and complications 
Pre-eclampsia/eclampsia 3.31 (1.78-6.43) 3.18 (1.81-5.72) 4.41 (1.29-15.0) 3.02 (1.20-7.61) 
Gestational hypertension 1.83 (1.10-3.04) 1.86 (1.12-3.08) 0.78 (0.26-2.33) - 
     
Delivery characteristics and complications 
Pregnancy length     
Normal gestation (37-42 weeks) 1.00 1.00 1.00 1.00 
Pre-term gestation (<37 weeks) 2.25 (1.50-3.38) 2.27 (1.51-3.40) 2.09 (1.39-3.13)1 1.90 (1.05-3.44) 
Pro-longed gestation (>42 weeks) 0.90 (0.52-1.57) 0.91 (0.57-1.57) 0.89 (0.49-1.60)1 1.02 (0.49-2.11) 
     
Mode of delivery     
Spontaneous  1.00 1.00 1.00 - 
Assisted delivery 1.38 (0.83-2.28) 1.41 (0.85-2.34) 1.29 (0.76-2.20)2 - 
Elective caesarean delivery 2.39 (1.55-3.68) 2.39 (1.55-3.69) 2.47 (1.58-3.85)2 - 
Emergency caesarean delivery  2.78 (1.93-4.01) 2.81 (1.95-4.05) 2.23 (1.50-3.33)2 - 
     
Stillbirth outcome 7.42 (3.64-15.1) 7.57 (3.71-15.4) 7.17 (3.33-15.4) 11.9 (5.43-26.1) 
Postpartum haemorrhage 1.93 (1.30-2.87) 1.93 (1.30-2.86) 1.78 (1.17-2.72) 2.35 (1.32-4.17) 
Puerperal infection  4.18 (2.72-6.43) 4.07 (2.64-6.28) 3.72 (2.32-5.97) 3.59 (1.85-6.96) 
Modelling framework (MF) 1: Models are built for each risk factor separately, adjusting for demographic and lifestyle 
characteristics only  
Modelling framework 2: As MF 1 and additionally adjusted for pre-existing co-morbidities 
Modelling framework 3: As MF 2 and additionally adjusted for pregnancy characteristics and complications 
**No VTE events to perform analysis 
1 Additionally adjusted for stillbirths 
2 Additionally adjusted for stillbirths, puerperal infection and postpartum haemorrhage  
◊Age taken as a continuous variable. 
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Table 3: Incidence rates of VTE per 100,000 person-years and IRRs during different periods of postpartum and around delivery  
 
 
1-3 weeks postpartum 
 
4-6 weeks postpartum 7-12 weeks postpartum 
 VTE Rate (95%CI)2 IRR (95%CI)1 VTE Rate(95%CI)2 IRR (95%CI)1 VTE Rate(95%CI)2 IRR (95%CI)1 
BMI≥30Kg/m2          
No 40 598 (438-815) 1.00 9 161 (84-311) 1.00 11 101 (56-182) 1.00 
Yes 27 1650 (1131-2406) 2.74 (1.66-4.52) 10 735 (395-1366) 4.18 (1.65-10.5) 3 112 (36-350) 0.97 (0.4-3.88) 
          
Preeclampsia/eclampsia          
No 119 814 (680-974) 1.00 27 221 (151-322) 1.00 18  75 (47-119) 1.00 
Yes 8 2263 (1131-4525) 2.54 (1.23-5.26) 4 1360 (510-3623) 5.41 (1.84-15.8) 2 349 (87-1397) 4.76 (1.05-21.6) 
          
Length of gestation           
Normal (36-42 weeks) 98 788 (646-960) 1.00 22 211 (139-321) 1.00 15 73 (44-122) 1.00 
Pre-term (<37 weeks) 20 1736 (1120-2691) 2.04 (1.26-3.28) 5 519 (216-1247) 1.92 (0.77-4.78) 4 213 (80-569) 2.81 (0.86-9.16) 
          
Caesarean section           
No 75 662 (528-831) 1.00 9 95 (49-182) 1.00 11 59 (33-107) 1.00 
Yes  52 1425 (1086-1870) 1.89 (1.30-2.74) 22 722 (475-1096) 6.99 (3.07-15.9) 9 151 (78-290) 2.22 (0.85-5.79) 
          
Postpartum haemorrhage          
No 103 756 (623-917) 1.00 27 237 (163-346) 1.00 18 81 (51-129) 1.00 
Yes 24 1778 (1192-2653) 2.22 (1.42-3.47) 4 347 (130-353) 1.38 (0.47-4.04) 2 88 (22-353) 1.00 (0.22-4.46) 
          
Puerperal infection           
No 114 775 (645-932) 1.00 28 230 (158-333) 1.00 18 76 (48-121) 1.00 
Yes 13 4813 (279-828) 5.99 (3.36-10.6) 3 899 (289-2787) 3.56 (1.08-11.7) 2 253 (63-1011) 3.27 (0.73-14.6) 
1Adjusted for demographic characteristics, pre-existing medical co-morbidities and pregnancy related complication and characteristics when not stratified by them  
2Rate per 100,000 person-years 
IRR: Incidence rate ratio 
CI: confidence interval 
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Table  4: Absolute rate of VTE per 100,000 pregnancies and number needed to treat (NNT) 
 
Risk factors 1-3 weeks 
postpartum 
4-6weeks 
postpartum 
7-12 weeks 
postpartum 
BMI≥30Kg/m2    
Rate (95%CI) 113 (74-164) 42 (20-77) 13 (2-37) 
NNT (50% risk reduction) 1,771 4,734 15,398 
NNT (88% risk reduction) 1,006 2,690 8,749 
    
Preeclampsia/eclampsia    
Rate (95%CI) 155 (67-305) 78 (21-200) 40 (48-145) 
NNT (50% risk reduction) 1,289 2,557 4,974 
NNT (88% risk reduction) 733 1,453 2,826 
    
Per-term birth     
Rate (95%CI) 119 (73-183) 30 (9-69) 24 (6-62) 
NNT (50% risk reduction) 1,683 6,700 8,249 
NNT( 88% risk reduction) 956 3,807 4,687 
    
Caesarean section     
Rate (95%CI) 98 (72-127) 42 (26-63) 17 (7-33) 
NNT (50% risk reduction) 2050 4816 11502 
NNT (88% risk reduction) 1,165 2,737 6,535 
    
Postpartum haemorrhage    
Rate (95%CI) 122 (78-181) 20 (5-51) 10.2 (1-36) 
NNT (50% risk reduction) 1,642 10,018 19,689 
NNT (88% risk reduction) 933 5,692 11,187 
    
Puerperal infection     
Rate (95%CI) 249 (15-38) 39 (8-114) 27 (3-96) 
NNT (50% risk reduction) 1173 5,090 7,479 
NNT (88% risk reduction) 667 2,892 4,249 
NOTE: Absolute rates per 100,000 are based on the number of pregnancies complicated by a particular risk factor (Table 1) divided by VTE events.  
It does not consider postpartum haemorrhage, puerperal infections as time varying covariates nor censor postpartum follow-up time after a VTE event.  
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Figure legends  
 
Figure 1: Conceptual hierarchical framework for multivariate modelling of risk factors 
for VTE during the postpartum period 
 
Figure 2: Absolute rate of VTE in the postpartum period by risk factors.  
  
29 
 
Figure 1: Conceptual hierarchical framework for multivariate modelling of risk factors 
for VTE during the postpartum period 
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Figure 2: Absolute rate of VTE in the postpartum period by risk factors.  
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Abbreviations: 
 
 
AR = Absolute Rate 
 
BMI = Body Mass Index  
 
CPRD = Clinical Practice Research Datalink 
 
HES = Hospital Episode Statistics  
 
IBD = Inflammatory Bowel Disease 
 
IRR = Incidence Rate Ratio 
 
NNT = Number Needed to Treat 
 
RCOG = Royal College of Obstetricians and Gynaecologists  
 
ACCP = American College of Chest Physician  
